title: Evaluation of the antiaggregant activity of ascorbyl phenolic esters with antioxidant properties.
abstract: Beneficial effects of the antioxidant L-ascorbic acid (Asc) in human health are well known. Its particular role in hemostasis deserves further consideration, since it has been described a dose-dependent effect of Asc in platelet activity. Contrary, it has been demonstrated that phenolic compounds have inhibitory effects on platelet aggregation stimulated by the physiological agonist thrombin (Thr). Here, we have evaluated the actions of three synthetic phenolic esters of Asc: L-ascorbyl 6-protocatechuate (Prot Asc), L-ascorbyl 6-gallate (Gal Asc), and L-ascorbyl 6-caffeate (Caf Asc). All these Asc derivatives exhibited greater radical scavenging activity than Asc, and in experiments using human platelets from healthy subjects, they do not evoke changes in platelet viability upon their administration. Nevertheless, these compounds altered platelet calcium homeostasis in response to Thr, although Prot Asc induced a smaller effect than Gal Asc, Caf Asc, and Asc. As a consequence, platelet aggregation was also impaired by these compounds, reporting Prot Asc and Caf Asc a weaker antiaggregant action than Gal Asc and Asc. Treatments with Gal Asc and Caf Asc altered in larger extent the phosphorylation pattern of pp60(Src) and mammalian target of rapamycin (mTOR) evoked by stimulating human platelets with Thr. Summarizing, Prot Asc is the ascorbyl phenolic ester with the strongest antioxidant properties and weakest antiaggregant actions, and its use as antioxidant may be safer than the rest of derivatives in order to prevent thrombotic alteration in patients that need treatment with antioxidant therapies.
authors.affiliation: Department of Physiology, University of Extremadura, Av. Universidad s/n, 10003, Cáceres, Spain.
authors.forename: Esther
authors.initials: E
authors.lastname: Lopez
authors.forename: María
authors.initials: M
authors.lastname: del Carmen Ortega-Liébana
authors.forename: Sofía
authors.initials: S
authors.lastname: Salido
authors.forename: Ginés M
authors.initials: GM
authors.lastname: Salido
authors.forename: Joaquín
authors.initials: J
authors.lastname: Altarejos
authors.forename: Juan A
authors.initials: JA
authors.lastname: Rosado
authors.forename: Pedro C
authors.initials: PC
authors.lastname: Redondo
mesh_terms: D001205:Ascorbic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology*; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology; D020013:Calcium Signaling; D004353:Drug Evaluation, Preclinical; D004952:Esters; D016166:Free Radical Scavengers / Q000494:pharmacology*; D006801:Humans; D010636:Phenols / Q000494:pharmacology; D010766:Phosphorylation; D010974:Platelet Aggregation; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D011499:Protein Processing, Post-Translational / Q000187:drug effects; D058570:TOR Serine-Threonine Kinases / Q000378:metabolism
chemical_list: D004952:Esters; D016166:Free Radical Scavengers; D010636:Phenols; D010975:Platelet Aggregation Inhibitors; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D001205:Ascorbic Acid